Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the 13th Clinical Trials on Alzheimer’s Disease (CTAD) Conference

SAN DIEGO–(BUSINESS WIRE)–Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that scientific presentations highlighting new analyses of pimavanserin clinical study data in dementia-related psychosis and neurodegenerative diseases will be shared at the 13th Clinical Trials on Alzheimer’s Disease Conference (CTAD), being held virtually November 4-7, 2020. Scientific presentations include those investigating pimavanserin treatment and its impact on cognition and motor function in patient

Click to view original post

Advertise With Us